Core One Labs Stock Price, News & Analysis

CLABF OTC

Company Description

Core One Labs Inc. (CLABF) is a pioneering life sciences biotechnology research and development company focusing on psychedelic medicines. The company, through its subsidiaries, is dedicated to bringing psychedelic compounds to market, advancing psychedelic-assisted treatments, and integrating novel delivery systems technology. With a multifaceted business approach, Core One holds a key interest in developing proprietary psilocybin production systems and formulations targeting neurological and mental health disorders. Their recent achievements include conducting animal model studies to evaluate bio-compounds' effectiveness in treating diseases like Alzheimer's, Parkinson's, Stroke, and Depression, showing promising results that could revolutionize the treatment landscape.

Stock Performance

Chart

$0.0625

0.00%

0.00

Last updated: April 26, 2025 at 12:42

- %

Performance 1 year

$4.9M

Market Cap

47.1M

Shares outstanding

Latest News

View All

December 8, 2023

30.20%

Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market

December 2, 2023

35.25%

Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods

August 4, 2023

13.30%

Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease

August 1, 2023

1.57%

Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass

July 28, 2023

4.57%

Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease

July 11, 2023

7.50%

Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin

SEC Filings

View All

No SEC filings available for Core One Labs.

Financial Highlights

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Core One Labs (CLABF)?

The current stock price of Core One Labs (CLABF) is $0.0625 as of April 25, 2025.

What is the market cap of Core One Labs (CLABF)?

The market cap of Core One Labs (CLABF) is approximately 4.9M.

What is Core One Labs Inc. known for?

Core One Labs Inc. is known for its focus on bringing psychedelic medicines to market, developing proprietary psilocybin production systems, and advancing psychedelic-assisted treatments.

What are some recent achievements of Core One Labs Inc.?

Core One Labs Inc. recently conducted animal model studies to evaluate bio-compounds' effectiveness in treating Alzheimer's, Parkinson's, Stroke, and Depression, showing promising results.

What is the business approach of Core One Labs Inc.?

Core One Labs Inc. has a multifaceted business approach, incorporating several complementary lines of businesses to establish itself as an industry leader in the rapidly growing psychedelics market space.

How does Core One Labs Inc. differentiate itself in the market?

Core One Labs Inc. stands out by focusing on the development of innovative psychedelic compounds, psychedelic-assisted treatments, and novel delivery systems technology to address neurological and mental health disorders.

What are the potential benefits of Core One Labs Inc.'s animal model studies?

The animal model studies conducted by Core One Labs Inc. have shown promising results, indicating the potential for transformative advancements in developing psychedelic drug formulations to target Parkinson's, Alzheimer's, Stroke, and Depression effectively.